Vaccinia virus targets rectal tumors in new immunotherapy combo
Disease control
Recruiting now
This phase I trial tests a modified vaccinia virus (BT-001) injected directly into rectal tumors, followed by a single dose of the immunotherapy drug pembrolizumab. The study enrolls about 20 adults with localized pMMR rectal cancer who are candidates for surgery. The main goal i…
Phase: PHASE1 • Sponsor: Henry Smith • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC